Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

The final economic data is in ahead of the election—here's what the numbers say about the Trump and Biden/Harris economies.

In our November stock market outlook ... In the three-month period between the beginning of November 2020 and the end of January 2021 — a period that included the election, the delay in ...

Tobacco giant Altria is the bluest of the blue-chip stocks, with a tremendous history of stability across even the stormiest stock market environments ... Benadryl back in 2022 via a spinoff ...

That momentum has continued throughout 2024, with all three major U.S. stock market indexes hitting ... slumping in 2021, 2022 and 2023. A big part of its multiyear decline was simply the ...

The Fed started increasing the federal funds rate in March 2022, and by the last hike in August 2023, it was at a two ... rates can be great for the stock market. It increases the borrowing ...

Roku (NASDAQ: ROKU) and Shopify (NYSE: SHOP) both experienced major growth spurts during the pandemic in 2020 and 2021. More ...

My annual selections for 2021 performed just ... from the portfolio for 2019 and 2020 were microchip companies that scored average gains of nearly 100%. For 2022, I like PepsiCo (PEP), which ...

The move was reversed in 2023 after the interest rates rose sharply in 2022. A swift reversal is uncommon for this series. When first implemented in 2021 ... part of the stock market.

Ulta Beauty revised its guidance downward, indicating a departure from its historical EPS growth. Find out what leads to a ...

At the same time, it managed to build up its Distribution & Services segment so that in 2023 ... of 7.2% from 2021 to 2028” ...

The 2021-22 incorporation ... half of 2023. But it was also overweight stocks coming into 2022, which hurt in the early stages of the bear market. The team did add value in 2020’s up-and-down ...